Nano-advantage in enhanced drug delivery with biodegradable nanoparticles: Contribution of reduced clearance

Drug Metabolism and Disposition

Volumn 40, Issue 7, 2012, Pages 1380-1388

  Kadam, Rajendra S ^a   Bourne, David W A ^a,b   Kompella, Uday B ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF OKLAHOMA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAMPTOTHECIN; CLOZAPINE; CYCLOSPORIN; EPIRUBICIN; IT 101; NANOPARTICLE; RUBITECAN; UNCLASSIFIED DRUG; VINPOCETINE;

ANIMAL EXPERIMENT; ARTICLE; BIODEGRADABILITY; COMPARTMENT MODEL; COMPUTER PROGRAM; DATA ANALYSIS; DOG; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; ENCAPSULATION; FEMALE; MALE; NANOTECHNOLOGY; NONHUMAN; PHARMACOKINETICS; PRIORITY JOURNAL; RAT; SURFACE CHARGE;

ADMINISTRATION, ORAL; ANIMALS; CHEMISTRY, PHARMACEUTICAL; DOGS; DRUG CARRIERS; DRUG COMPOUNDING; DRUG DELIVERY SYSTEMS; FEMALE; INJECTIONS, INTRAVENOUS; MALE; NANOPARTICLES; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; RATS; RATS, SPRAGUE-DAWLEY; RATS, WISTAR;

EID: 84862660378     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.112.044925     Document Type: Article

References (53)

1. Alexis F, Pridgen E, Molnar LK, and Farokhzad OC (2008) Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm 5:505-515.
2. Anand P, Kunnumakkara AB, Newman RA, and Aggarwal BB (2007) Bioavailability of curcumin: problems and promises. Mol Pharm 4:807-818.
3. Andresen TL, Jensen SS, and Jørgensen K (2005) Advanced strategies in liposomal cancer therapy: problems and prospects of active and tumor specific drug release. Prog Lipid Res 44:68-97.
4. Bargoni A, Cavalli R, Caputo O, Fundarò A, Gasco MR, and Zara GP (1998) Solid lipid nanoparticles in lymph and plasma after duodenal administration to rats. Pharm Res 15:745-750.
5. Bawa R (2008) Nanoparticle-based therapeutics in humans: a survey. Nanotechnol Law Bus 5:135-155.
6. Bourne DW (1989) BOOMER, a simulation and modeling program for pharmacokinetic and pharmacodynamic data analysis. Comput Methods Programs Biomed 29:191-195.
7. Choi HS, Liu W, Misra P, Tanaka E, Zimmer JP, Itty Ipe B, Bawendi MG, and Frangioni JV (2007) Renal clearance of quantum dots. Nat Biotechnol 25:1165-1170.
8. Chonn A, Semple SC, and Cullis PR (1992) Association of blood proteins with large unilamellar liposomes in vivo. Relation to circulation lifetimes. J Biol Chem 267:18759-18765.
9. Chow DS, Gong L, Wolfe MD, and Giovanella BC (2000) Modified lactone/carboxylate salt equilibria in vivo by liposomal delivery of 9-nitro-camptothecin. Ann NY Acad Sci 922:164-174.
10. Dadashzadeh S, Derakhshandeh K, and Shirazi FH (2008) 9-Nitrocamptothecin polymeric nanoparticles: cytotoxicity and pharmacokinetic studies of lactone and total forms of drug in rats. Anticancer Drugs 19:805-811.
11. El-Laithy HM, Shoukry O, and Mahran LG (2011) Novel sugar esters proniosomes for transdermal delivery of vinpocetine: preclinical and clinical studies. Eur J Pharm Biopharm 77:43-55.
12. El-Shabouri MH (2002) Positively charged nanoparticles for improving the oral bioavailability of cyclosporin-A. Int J Pharm 249:101-108.
13. Emerich DF and Thanos CG (2006) The pinpoint promise of nanoparticle-based drug delivery and molecular diagnosis. Biomol Eng 23:171-184.
14. Florence AT (2005) Nanoparticle uptake by the oral route: fulfilling its potential? Drug Discov Today 2:75-81.
15. Florence AT, Hillery AM, Hussain N, and Jani PU (1995a) Factors affecting the oral uptake and translocation of polystyrene nanoparticles: histological and analytical evidence. J Drug Target 3:65-70.
16. Florence AT, Hillery AM, Hussain N, and Jani PU (1995b) Nanoparticles as carriers for oral peptide absorption: studies on particle uptake and fate. J Control Release 36:39-46.
17. Gelperina S, Kisich K, Iseman MD, and Heifets L (2005) The potential advantages of nanoparticle drug delivery systems in chemotherapy of tuberculosis. Am J Respir Crit Care Med 172:1487-1490.
18. Gref R, Minamitake Y, Peracchia MT, Trubetskoy V, Torchilin V, and Langer R (1994) Biodegradable long-circulating polymeric nanospheres. Science 263:1600-1603.
19. Grislain L, Couvreur P, Lenaerts V, Roland M, Deprez-Decampeneere D, and Speiser P (1983) Pharmacokinetics and distribution of a biodegradable drug-carrier. Int J Pharm 15:335-345.
20. Gurney HP, Ackland S, Gebski V, and Farrell G (1998) Factors affecting epirubicin pharmacokinetics and toxicity: evidence against using body-surface area for dose calculation. J Clin Oncol 16:2299-2304.
21. Harrington KJ, Lewanski CR, Northcote AD, Whittaker J, Wellbank H, Vile RG, Peters AM, and Stewart JS (2001) Phase I-II study of pegylated liposomal cisplatin (SPI-077) in patients with inoperable head and neck cancer. Ann Oncol 12:493-496.
22. Hussain N, Jani PU, and Florence AT (1997) Enhanced oral uptake of tomato lectin-conjugated nanoparticles in the rat. Pharm Res 14:613-618.
23. Italia JL, Bhatt DK, Bhardwaj V, Tikoo K, and Kumar MN (2007) PLGA nanoparticles for oral delivery of cyclosporine: nephrotoxicity and pharmacokinetic studies in comparison to Sandimmune Neoral. J Control Release 119:197-206.
24. Levchenko TS, Rammohan R, Lukyanov AN, Whiteman KR, and Torchilin VP (2002) Liposome clearance in mice: the effect of a separate and combined presence of surface charge and polymer coating. Int J Pharm 240:95-102.
25. Li K, Chen X, Zhong D, and Li Y (2003) Identification of the metabolites of 9-nitro-20(S)-camptothecin in rats. Drug Metab Dispos 31:792-797.
26. Li L, Gao FP, Tang HB, Bai YG, Li RF, Li XM, Liu LR, Wang YS, and Zhang QQ (2010) Self-assembled nanoparticles of cholesterol-conjugated carboxymethyl curdlan as a novel carrier of epirubicin. Nanotechnology 21:265601.
27. Li SD and Huang L (2008) Pharmacokinetics and biodistribution of nanoparticles. Mol Pharm 5:496-504.
28. Lin JH and Lu AY (1997) Role of pharmacokinetics and metabolism in drug discovery and development. Pharmacol Rev 49:403-449.
29. Ling G, Zhang P, Zhang W, Sun J, Meng X, Qin Y, Deng Y, and He Z (2010) Development of novel self-assembled DS-PLGA hybrid nanoparticles for improving oral bioavailability of vincristine sulfate by P-gp inhibition. J Control Release 148:241-248.
30. Luo Y, Chen D, Ren L, Zhao X, and Qin J (2006) Solid lipid nanoparticles for enhancing vinpocetine's oral bioavailability. J Control Release 114:53-59.
31. Manjunath K and Venkateswarlu V (2005) Pharmacokinetics, tissue distribution and bioavailability of clozapine solid lipid nanoparticles after intravenous and intraduodenal administration. J Control Release 107:215-228.
32. Mishra VK, Mohammad G, and Mishra SK (2008) Downregulation of telomerase activity may enhanced by nanoparticle mediated curcumin delivery. Dig J Nanomater Biostruct 3:163-169.
33. Mittal G and Kumar MN (2009) Impact of polymeric nanoparticles on oral pharmacokinetics: a dose-dependent case study with estradiol. J Pharm Sci 98:3730-3734.
34. Mittal G, Sahana DK, Bhardwaj V, and Ravi Kumar MN (2007) Estradiol loaded PLGA nanoparticles for oral administration: effect of polymer molecular weight and copolymer composition on release behavior in vitro and in vivo. J Control Release 119:77-85.
35. Papahadjopoulos D, Allen TM, Gabizon A, Mayhew E, Matthay K, Huang SK, Lee KD, Woodle MC, Lasic DD, and Redemann C (1991) Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc Natl Acad Sci USA 88:11460-11464.
36. Parkinson A, Ogilive BW, Paris BL, Hensely TN, and Loewen GJ (2010) Human biotransformation, in Biotransformation and Metabolite Elucidation of Xenobiotics. John Wiley & Sons, New York.
37. Petros RA and DeSimone JM (2010) Strategies in the design of nanoparticles for therapeutic applications. Nat Rev Drug Discov 9:615-627.
38. Piskin E, Tuncel A, Denizli A, and Ayhan H (1994) Monosize microbeads based on polystyrene and their modified forms for some selected medical and biological applications. J Biomater Sci Polym Ed 5:451-471.
39. Qian F, Cui F, Ding J, Tang C, and Yin C (2006) Chitosan graft copolymer nanoparticles for oral protein drug delivery: preparation and characterization. Biomacromolecules 7:2722-2727.
40. Roser M, Fischer D, and Kissel T (1998) Surface-modified biodegradable albumin nano- and microspheres. II: effect of surface charges on in vitro phagocytosis and biodistribution in rats. Eur J Pharm Biopharm 46:255-263.
41. Schluep T, Cheng J, Khin KT, and Davis ME (2006) Pharmacokinetics and biodistribution of the camptothecin-polymer conjugate IT-101 in rats and tumor-bearing mice. Cancer Chemother Pharmacol 57:654-662.
42. Scott DO, Bindra DS, and Stella VJ (1993) Plasma pharmacokinetics of lactone and carboxylate forms of 20(S)-camptothecin in anesthetized rats. Pharm Res 10:1451-1457.
43. Sinha R, Kim GJ, Nie S, and Shin DM (2006) Nanotechnology in cancer therapeutics: bioconjugated nanoparticles for drug delivery. Mol Cancer Ther 5:1909-1917.
44. Slepushkin VA, Simões S, Dazin P, Newman MS, Guo LS, Pedroso de Lima MC, and Düzgüneş N (1997) Sterically stabilized pH-sensitive liposomes. Intracellular delivery of aqueous contents and prolonged circulation in vivo. J Biol Chem 272:2382-2388.
45. Takeuchi H, Yamamoto H, Niwa T, Hino T, and Kawashima Y (1996) Enteral absorption of insulin in rats from mucoadhesive chitosan-coated liposomes. Pharm Res 13:896-901.
46. Torché AM, Jouan H, Le Corre P, Albina E, Primault R, Jestin A, and Le Verge R (2000) Ex vivo and in situ PLGA microspheres uptake by pig ileal Peyer's patch segment. Int J Pharm 201:15-27.
47. Vereczkey L, Czira G, Tamás J, Szentirmay Z, Botár Z, and Szporny L (1979) Pharmacokinetics of vinpocetine in humans. Arzneimittelforschung 29:957-960.
48. Verrecchia T, Spenlehauer G, Bazile DV, Murry-Brelier A, Archimbaud Y, and Veillard M (1995) Non-stealth (poly(lactic acid/albumin)) and stealth (poly(lactic acid-polyethylene glycol)) nanoparticles as injectable drug carriers. J Control Release 36:49-61.
49. Xu F, Yuan Y, Shan X, Liu C, Tao X, Sheng Y, and Zhou H (2009) Long-circulation of hemoglobin-loaded polymeric nanoparticles as oxygen carriers with modulated surface charges. Int J Pharm 377:199-206.
50. Yamamoto Y, Nagasaki Y, Kato Y, Sugiyama Y, and Kataoka K (2001) Long-circulating poly(ethylene glycol)-poly(D,L-lactide) block copolymer micelles with modulated surface charge. J Control Release 77:27-38.
51. Zhang C, Newsome JT, Mewani R, Pei J, Gokhale PC, and Kasid UN (2009) Systemic delivery and pre-clinical evaluation of nanoparticles containing antisense oligonucleotides and siRNAs. Methods Mol Biol 480:65-83.
52. Zhang L, Gu FX, Chan JM, Wang AZ, Langer RS, and Farokhzad OC (2008) Nanoparticles in medicine: therapeutic applications and developments. Clin Pharmacol Ther 83:761-769.
53. Zweers ML, Engbers GH, Grijpma DW, and Feijen J (2006) Release of anti-restenosis drugs from poly(ethylene oxide)-poly(DL-lactic-co-glycolic acid) nanoparticles. J Control Release 114:317-324.